Your browser is no longer supported. Please, upgrade your browser.
HRTX Heron Therapeutics, Inc. daily Stock Chart
Heron Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own0.13% Shs Outstand90.75M Perf Week-1.27%
Market Cap1.43B Forward P/E- EPS next Y-1.66 Insider Trans-0.96% Shs Float90.74M Perf Month-0.19%
Income-198.30M PEG- EPS next Q-0.63 Inst Own99.40% Short Float18.78% Perf Quarter-7.52%
Sales125.80M P/S11.37 EPS this Y-2.50% Inst Trans0.37% Short Ratio23.02 Perf Half Y7.72%
Book/sh3.57 P/B4.34 EPS next Y32.80% ROA-43.60% Target Price- Perf Year-16.65%
Cash/sh3.26 P/C4.76 EPS next 5Y47.50% ROE-57.50% 52W Range9.60 - 26.81 Perf YTD-34.09%
Dividend- P/FCF- EPS past 5Y2.70% ROI-51.50% 52W High-42.22% Beta1.62
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin59.40% 52W Low61.35% ATR0.63
Employees231 Current Ratio4.20 Sales Q/Q-38.10% Oper. Margin- RSI (14)53.58 Volatility3.33% 4.03%
OptionableYes Debt/Eq0.02 EPS Q/Q3.70% Profit Margin- Rel Volume0.70 Prev Close15.40
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume740.51K Price15.49
Recom1.60 SMA202.11% SMA502.74% SMA200-7.37% Volume522,336 Change0.58%
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jan-03-18Initiated Leerink Partners Outperform $22
Sep-27-17Initiated Northland Capital Outperform $40
Feb-27-17Initiated Needham Buy $28
Oct-26-16Initiated Aegis Capital Buy
Sep-06-16Resumed Lake Street Buy $45
May-03-16Initiated Cantor Fitzgerald Buy
Dec-10-15Initiated Lake Street Buy $45
Sep-23-15Reiterated Leerink Partners Outperform $38 → $57
Sep-02-15Initiated BofA/Merrill Buy $46
Aug-03-15Reiterated Brean Capital Buy $40 → $45
Jun-30-15Reiterated JMP Securities Mkt Outperform $25 → $33
Jun-19-15Reiterated Leerink Partners Outperform $26 → $38
Aug-07-14Initiated Noble Financial Buy $18
Oct-14-20 08:10AM  
Oct-06-20 05:05PM  
Sep-29-20 11:42AM  
Sep-28-20 08:30AM  
Sep-16-20 08:30AM  
Sep-11-20 04:05PM  
Sep-09-20 10:19AM  
Sep-08-20 08:30AM  
Aug-29-20 10:23AM  
Aug-12-20 01:00AM  
Aug-05-20 06:35PM  
Aug-04-20 11:26AM  
Jul-27-20 12:31PM  
Jul-24-20 10:29AM  
Jul-16-20 08:30AM  
Jul-02-20 10:38PM  
Jul-01-20 02:26PM  
Jun-30-20 11:15AM  
Jun-29-20 08:47AM  
Jun-26-20 08:28AM  
Jun-23-20 07:51PM  
Jun-21-20 02:53PM  
Jun-16-20 10:00AM  
Jun-04-20 09:00AM  
May-20-20 10:04AM  
May-18-20 09:00AM  
May-09-20 08:00AM  
May-08-20 10:04AM  
May-06-20 10:35AM  
May-05-20 07:31AM  
Apr-19-20 07:02AM  
Apr-09-20 04:05PM  
Apr-07-20 03:33PM  
Apr-05-20 09:57AM  
Mar-02-20 09:05AM  
Feb-27-20 01:19PM  
Feb-26-20 04:42PM  
Feb-21-20 12:30PM  
Feb-20-20 07:06AM  
Feb-19-20 06:16PM  
Feb-18-20 04:05PM  
Jan-27-20 11:01AM  
Jan-22-20 08:53AM  
Jan-13-20 08:30AM  
Dec-21-19 08:27AM  
Dec-16-19 04:05PM  
Dec-12-19 01:44PM  
Dec-10-19 05:18AM  
Dec-06-19 08:00AM  
Dec-03-19 07:30AM  
Nov-26-19 04:05PM  
Nov-25-19 09:13AM  
Nov-22-19 03:22PM  
Nov-15-19 09:00AM  
Nov-14-19 04:05PM  
Nov-13-19 04:05PM  
Nov-12-19 09:45AM  
Nov-11-19 01:59PM  
Oct-30-19 10:33AM  
Oct-28-19 09:08AM  
Oct-22-19 08:30AM  
Oct-07-19 12:14PM  
Oct-04-19 10:00PM  
Oct-03-19 10:37PM  
Oct-02-19 12:23PM  
Oct-01-19 04:10PM  
Sep-25-19 04:05PM  
Sep-04-19 10:00AM  
Aug-30-19 06:14PM  
Aug-29-19 07:31AM  
Aug-20-19 08:30AM  
Aug-06-19 03:40PM  
Aug-05-19 03:30PM  
Aug-02-19 03:30PM  
Aug-01-19 04:00PM  
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MANHARD KIMBERLYExecutive VP, Drug DevelopmentMay 01Sale13.971,15816,1760May 01 06:48 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 29Option Exercise13.0024,000312,00024,000Dec 03 06:30 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 29Sale26.0024,000624,0000Dec 03 06:30 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.